3218 Stock Overview
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China.
No risks detected for 3218 from our risk checks.
Universal Vision Biotechnology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$298.50|
|52 Week High||NT$353.50|
|52 Week Low||NT$210.00|
|1 Month Change||-11.21%|
|3 Month Change||10.56%|
|1 Year Change||2.09%|
|3 Year Change||503.90%|
|5 Year Change||1,073.88%|
|Change since IPO||1,471.93%|
Recent News & Updates
|3218||TW Healthcare||TW Market|
Return vs Industry: 3218 underperformed the TW Healthcare industry which returned 10.7% over the past year.
Return vs Market: 3218 exceeded the TW Market which returned -15.9% over the past year.
|3218 Average Weekly Movement||6.0%|
|Healthcare Industry Average Movement||4.6%|
|Market Average Movement||5.0%|
|10% most volatile stocks in TW Market||8.2%|
|10% least volatile stocks in TW Market||2.4%|
Stable Share Price: 3218 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 3218's weekly volatility (6%) has been stable over the past year.
About the Company
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinics provide laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting.
Universal Vision Biotechnology Fundamentals Summary
|3218 fundamental statistics|
Is 3218 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|3218 income statement (TTM)|
|Cost of Revenue||NT$1.16b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||8.99|
|Net Profit Margin||23.71%|
How did 3218 perform over the long term?See historical performance and comparison
1.6%Current Dividend Yield
Is 3218 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3218?
Other financial metrics that can be useful for relative valuation.
|What is 3218's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 3218's PE Ratio compare to its peers?
|3218 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
8403 ShareHope Medicine
6879 TCI GENE
4139 Ma Kuang Healthcare Holding
3218 Universal Vision Biotechnology
Price-To-Earnings vs Peers: 3218 is good value based on its Price-To-Earnings Ratio (33.2x) compared to the peer average (61.2x).
Price to Earnings Ratio vs Industry
How does 3218's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 3218 is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the Asian Healthcare industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is 3218's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||33.2x|
|Fair PE Ratio||31.9x|
Price-To-Earnings vs Fair Ratio: 3218 is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the estimated Fair Price-To-Earnings Ratio (31.9x).
Share Price vs Fair Value
What is the Fair Price of 3218 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3218 (NT$298.5) is trading below our estimate of fair value (NT$843.74)
Significantly Below Fair Value: 3218 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Universal Vision Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3218's forecast earnings growth (31.2% per year) is above the savings rate (0.7%).
Earnings vs Market: 3218's earnings (31.2% per year) are forecast to grow faster than the TW market (7% per year).
High Growth Earnings: 3218's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 3218's revenue (21% per year) is forecast to grow faster than the TW market (7.9% per year).
High Growth Revenue: 3218's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3218's Return on Equity is forecast to be high in 3 years time (35.9%)
Discover growth companies
How has Universal Vision Biotechnology performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3218 has high quality earnings.
Growing Profit Margin: 3218's current net profit margins (23.7%) are higher than last year (23.2%).
Past Earnings Growth Analysis
Earnings Trend: 3218's earnings have grown significantly by 38.3% per year over the past 5 years.
Accelerating Growth: 3218's earnings growth over the past year (29.3%) is below its 5-year average (38.3% per year).
Earnings vs Industry: 3218 earnings growth over the past year (29.3%) exceeded the Healthcare industry 14.6%.
Return on Equity
High ROE: 3218's Return on Equity (30.9%) is considered high.
Discover strong past performing companies
How is Universal Vision Biotechnology's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 3218's short term assets (NT$1.8B) exceed its short term liabilities (NT$906.1M).
Long Term Liabilities: 3218's short term assets (NT$1.8B) exceed its long term liabilities (NT$745.5M).
Debt to Equity History and Analysis
Debt Level: 3218 has more cash than its total debt.
Reducing Debt: 3218's debt to equity ratio has increased from 0.2% to 6.1% over the past 5 years.
Debt Coverage: 3218's debt is well covered by operating cash flow (895.7%).
Interest Coverage: 3218's interest payments on its debt are well covered by EBIT (98.7x coverage).
Discover healthy companies
What is Universal Vision Biotechnology current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3218's dividend (1.6%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.45%).
High Dividend: 3218's dividend (1.6%) is low compared to the top 25% of dividend payers in the TW market (6.68%).
Stability and Growth of Payments
Stable Dividend: 3218's dividend payments have been volatile in the past 10 years.
Growing Dividend: 3218's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (52.9%), 3218's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (46.2%), 3218's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Kenneth Lu is President of Universal Vision Biotechnology Co., Ltd. since February 1, 2010. Mr. Lu has M.B.A. from National Taiwan University.
Experienced Management: 3218's management team is seasoned and experienced (11.3 years average tenure).
Experienced Board: 3218's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Universal Vision Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Universal Vision Biotechnology Co., Ltd.
- Ticker: 3218
- Exchange: TPEX
- Founded: 1992
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: NT$23.859b
- Shares outstanding: 79.93m
- Website: https://www.eyecenter.com.tw
Number of Employees
- Universal Vision Biotechnology Co., Ltd.
- No.3-1 Yuanqu Street
- 4th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|3218||TPEX (Taipei Exchange)||Yes||Common Stock||TW||TWD||Jan 2004|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.